Data from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma

Abstract

<div>AbstractPurpose:<p>Effective treatment of locally advanced or metastatic urothelial carcinoma (mUC) remains an unmet need. Antibody–drug conjugates (ADC) providing targeted drug delivery have shown antitumor activity in this setting. AGS15E is an investigational ADC that delivers the cytotoxic drug monomethyl auristatin E to cells expressing SLITRK6, a UC-associated antigen.</p>Patients and Methods:<p>This was a multicenter, single-arm, …

Authors

Petrylak DP; Eigl BJ; George S; Heath EI; Hotte SJ; Chism DD; Nabell LM; Picus J; Cheng SY; Appleman LJ

Publication Date

January 5, 2024

DOI

10.1158/1078-0432.c.7010460

Associated Experts

Sebastien Hotte

Professor, Faculty of Health Sciences

Visit profile

View published work (Non-McMaster Users)